News for Fortress Biotech Stock (FBIO)

Journey Medical Corporation Expects Topline Results from the Phase 3 Clinical Trials (MVOR-1 and MVOR-2) Evaluating DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) for the Treatment of Papulopustular Rosacea to be Announced Week of Jul

GlobeNewsWire • 07/03/23

Urica Therapeutics Announces Topline Data from the Phase 1 Clinical Trial Evaluating Dotinurad in Healthy Volunteers in the United States

GlobeNewsWire • 06/29/23

Helocyte Announces $3.22 Million Grant from the National Cancer Institute for Triplex Phase 2 Clinical Trial Program

GlobeNewsWire • 06/15/23

Journey Medical Corporation Announces Positive Topline Data from Phase 1 Clinical Trial Assessing the Impact of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) on Microbial Flora of Healthy Adult Subjects

GlobeNewsWire • 06/13/23

Journey Medical Corporation Reports First Quarter 2023 Financial Results and Recent Corporate Highlights

GlobeNewsWire • 05/22/23

Journey Medical Corporation to Announce First Quarter 2023 Financial Results on May 22, 2023

GlobeNewsWire • 05/19/23

Fortress Biotech (FBIO) Reports Q1 Loss, Lags Revenue Estimates

Zacks Investment Research • 05/15/23

Fortress Biotech Reports First Quarter 2023 Financial Results and Recent Corporate Highlights

GlobeNewsWire • 05/15/23

Earnings Preview: Fortress Biotech (FBIO) Q1 Earnings Expected to Decline

Zacks Investment Research • 05/04/23

Journey Medical Corporation to Announce First Quarter 2023 Financial Results on May 11, 2023

GlobeNewsWire • 05/04/23

Aevitas Therapeutics, a Fortress Biotech Subsidiary, Announces Asset Purchase Agreement with 4D Molecular Therapeutics for World-Wide Rights to Aevitas' Short-Form Human Complement Factor H

GlobeNewsWire • 04/24/23

Fortress Biotech Reports Record 2022 Financial Results and Recent Corporate Highlights

GlobeNewsWire • 03/30/23

Journey Medical Corporation Reports Full-Year 2022 Financial Results and Recent Corporate Highlights

GlobeNewsWire • 03/29/23

Journey Medical Corporation to Announce Year End 2022 Financial Results on March 29, 2023

GlobeNewsWire • 03/22/23

Journey Medical Corporation Announces Completion of Treatment Assessing Impact of DFD-29 (Minocycline Modified Release Capsules 40 mg) on Microbial Flora in a Separate Phase 1 Clinical Trial

GlobeNewsWire • 03/16/23

Journey Medical Corporation to Participate in the 35th Annual ROTH Conference

GlobeNewsWire • 03/07/23

Fortress Biotech to Participate in Two March 2023 Investor Conferences

GlobeNewsWire • 03/07/23

Helocyte, Inc. Announces Positive Data from Stem Cell Transplant Donor Vaccination Trial to be Presented at the 2023 Tandem Meetings: Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR

GlobeNewsWire • 02/16/23

Study Published in American Journal of Hematology Demonstrates First Reported Evidence of Safe and Successful Boosting of Cytomegalovirus Vaccine-Specific T Cell Immunity in a Stem Cell Transplant Recipient Via Vaccination of a Donor with Triplex

GlobeNewsWire • 02/15/23

Fortress Biotech Announces Closing of $13.9 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules

GlobeNewsWire • 02/10/23

Fortress Biotech Announces Pricing of $13.9 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules

GlobeNewsWire • 02/08/23

Aegis Capital Corp. Acted as Exclusive Placement Agent on a $3.25 Million Registered Direct & Private Placement for Avenue Therapeutics, Inc. (NASDAQ:ATXI)

Accesswire • 01/31/23

Journey Medical Corporation Appoints Joseph Benesch as Interim Chief Financial Officer

GlobeNewsWire • 01/20/23

Journey Medical Corporation Completes Enrollment in Phase 3 Clinical Trials Evaluating DFD-29 (Minocycline Modified Release Capsules 40 mg) for the Treatment of Papulopustular Rosacea

GlobeNewsWire • 01/10/23

Journey Medical Corporation Announces Positive Comparative Pharmacokinetic (PK) Data for DFD-29

GlobeNewsWire • 12/20/22